Key Takeaways
- Flat quarter, recovery deferred: Volume growth in chemicals was offset by sustained pricing pressure, pushing the expected relief out by at least one more quarter.
- Chemical volumes surged but prices lagged: The chemical segment saw volume jump >15% QoQ, yet revenue declined because realizations stayed below last year's levels.
- Ibuprofen margins have bottomed, then softened again: Margins were stable for three quarters, but prices dipped in the last few days, adding fresh uncertainty.
- New land acquisition signals medium-term capacity build: A new facility on the Chandigarh-Bhatinda Highway targets an 18-24 month ramp-up, with products still being finalized.
- What to watch next quarter: Whether the promised demand and pricing recovery actually begins in Q1 FY26, any progress on USFDA inspection timing, and the trajectory of ibuprofen prices after the recent softening.
Demand & Pricing Environment
- Consumption slowdown biting: A broader consumption slowdown is creeping in and impacting growth; the trade war does not augur well for Indian pharma and chemicals, and Q3 was flat for the industry and IOL alike.
- API pricing subdued: API prices remain under pressure amid stagnant demand, though reduced input costs and operational efficiencies provided some margin support.
- Specialty chemicals mixed: Raw material and finished goods prices have stabilized, but export realizations softened to some extent even as demand improved.
- Chemical revenue paradox: Revenue declined despite stable or increased volumes, purely because prices were lower than last year; raw material prices also decreased, but not enough to fully offset.
- Export fall driven by price, not volume: The prime reason for the export decline is reduction in prices, especially in the non-Ibuprofen segment.
- Q4 relief now deferred: Management had earlier expected relief from Q4 onwards, but now sees that deferring by one more quarter; Q4 does not seem any different, with pricing pressure and demand stagnancy persisting.
Abhay Raj Singh: "Earlier, we were expecting that there will be some relief from Q4 onwards. But I think now this is deferring by one more quarter."
Segment Performance
| Segment | Trend | Commentary |
|---|---|---|
| Chemicals | ▲ Volume, ▼ Price | Volume up >15% QoQ; revenue declined on lower realizations. Margins improved on stable raw material prices, operational efficiency, capacity utilization, and new market exploration including REACH-certified ethyl acetate exports to Europe. |
| Ibuprofen API | ▬ Stable, then softening | Margins stable and bottomed out for three quarters, but prices softened again in the last few days. Capacity utilization targeted to reach ~90% in the next two to three quarters. |
| Non-Ibuprofen API | ▲ Modest growth | 6% growth driven by Metformin and Pantoprazole. Client validation in European and Latin American markets is in process with trial orders and samples; better export prices expected to drive future revenue. |
| Acetic Anhydride | ▲ New contributor | Plant commercialized last year; exports now beginning, which should fetch better prices. |
- Logistics costs sustained: Logistic challenges due to rise in freight costs have persisted, limiting the extent of cost reduction.
- Depreciation increase: Driven by capitalization of the acetic anhydride plant, revamping of the cogeneration plant, and environmental equipment and ETP.
Strategic Initiatives & Regulatory Progress
- New land acquisition: Land acquired on the Chandigarh-Bhatinda Highway for a new facility; the business model will remain the same with chemicals and API plants. Products are in the process of finalization, and environmental approvals have been applied for. Management hopes to ramp up the facility in 18 to 24 months.
- ANDA filings underway: 2-3 molecules have been filed (ANDA) for the company, marking a step toward regulated market access.
- CEP approval for Mesalazine: Received recently; commercial production has not yet started in a big manner, and the market is still being explored.
- REACH Certification: Obtained around last year, enabling ethyl acetate exports to Europe and supporting the chemical segment's market diversification.
- USFDA inspection timing uncertain: Management expects a USFDA inspection during the ANDA evaluation process, as it is technically mandatory for the US to visit the facility before approving any ANDA. However, the company is absolutely not in a position to communicate the timing. All 10 plants were inspected by ANVISA last year with no objections, and the company remains audit-ready at all times, handling 3-4 customer audits every month.
- Non-Ibuprofen regulated market entry: USFDA approval for non-Ibu products will boost sales in existing regulated markets, but the timeline is beyond the company's control.
Margins & Cost Structure
- Margin pressure from pricing: Segment demand and pricing pressure continue to impact margin and revenue growth; cost-corrective measures, volume-led economies of scale, and enhanced operational efficiencies minimized the impact.
- Chemical margin improvement drivers: Stable raw material and finished goods prices (stable for the last 2-3 quarters after 5-6 quarters of volatility), operational efficiency, capacity utilization, increased store market volume, and new market exploration.
- Double-digit operating profit margin timeline: Management expects improvement from Q1 or Q2 next year (FY26) as pricing pressures ease; pricing pressure has been felt for the last 2-3 quarters despite maintained or increased quantity.
Abhay Raj Singh: "So expectation is one thing. Estimate is another thing. So what we are estimating that from Q2 onwards we will find some or may be Q1 onwards, next year we will start seeing the improvement in the pricing pressures..."
Capital Management & Shareholder Returns
- Interim dividend declared: Board declared a 40% interim dividend (₹4 per share of face value ₹10 each) for FY 2024-25, with a record date of 18th February 2025, to be paid within the month.
- Stock split approved: Board fixed 11th March 2025 as the record date for the sub-division of equity shares from a face value of ₹10 to ₹2, subject to shareholder approval. The rationale cited continuous demand from shareholders and the aim to provide greater liquidity to retail investors. Shares were around ₹425 when the split was considered, but negative market sentiment subsequently affected the price. Management remains hopeful that prices will increase along with improving market sentiments.
Competitive & External Risks
- Competitor ibuprofen capacity: A competitor from Hyderabad has been attempting to enter for 2-3 years with no major impact seen so far; the competitor is operating at very low capacity utilization.
- Tariff exposure uncertain: The company does not export chemicals directly to the US and cannot calculate the impact of reciprocal tariffs. Management does not have clarity on the origins of competitive products exported to the US and prefers to let the situation stabilize.
Abhay Raj Singh: "Do not have that much of idea. But the tariff is what the U.S. is saying that they will be reciprocating the tariff... That may impact, but indirectly, not directly."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Ibuprofen capacity utilization | Reach ~90% | Next 2-3 quarters |
| New land facility ramp-up | Facility operational | 18-24 months |
| EBITDA margin (company level) | 13% to 15% | Not specified |
| Topline growth | 10% to 12% | Considering current scenario |
| EBITDA margin target | 14% to 15% | When prices recover |
| Double-digit operating profit margin | Improvement begins | Q1 or Q2 FY26 |
| Export share target | 40% to 45% of total revenue | Not specified |
| Demand and pricing recovery | Pick-up in pharma and chemical sector | FY26 |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Total standalone income | ₹527 cr, vs ₹529 cr in Q3 FY24 and ₹532 cr in Q2 FY25 |
| EBITDA | ₹51 cr, vs ₹53 cr in Q3 FY24 and ₹48 cr in Q2 FY25 |
| EBITDA margin | 9.7%, vs 10% in Q3 FY24 and 9% in Q2 FY25 |
| Net profit | ₹21 cr, vs ₹23 cr in Q3 FY24 and ₹19 cr in Q2 FY25 |
| EBIT margin, pharmaceutical segment | 8.7% |
| EBIT margin, specialty chemical segment | 2.1% |
| CAPEX | ₹54 cr, vs ₹80 cr in Q3 FY24 and ₹83 cr in Q2 FY25 |
| Interim dividend | ₹4 per share (40% of face value ₹10), record date 18 Feb 2025 |
| Stock split record date | 11 March 2025, face value sub-divided to ₹2 from ₹10 |
| Ibuprofen capacity utilization | ~75%, targeting ~90% in next 2-3 quarters |
| Ibuprofen average price | ~$9, margins stable but prices softened in recent days |
| Volume growth, chemical sector | >15% QoQ |
| Volume growth, API segment (Ibu and non-Ibu) | ~1-2%, almost stable |
| Non-Ibuprofen portfolio growth | 6% this quarter, driven primarily by Metformin and Pantoprazole |
| Chemical revenue | ₹275 cr, 4% decline due to price despite volume increase |
| Topline growth guidance | 10-12%, considering current scenario |
| EBITDA margin expectation, company as a whole | 13-15% |
| Export share target | 40-45% for the company as a whole |